Our highly-skilled team of histotechnicians under the supervision of experienced pathologists perform the male fertility evaluations in rats and mice. The studies are conducted with speed and rigor and the study designs are highly customized to cater to the client product development purposes. We also offer standalone services as required by the clients for performing standalone histopathology or clinical pathology services.
A separate set of additional animals are kept for the vehicle control group for comparison of test item induced changes. The doses are selected based on a dose range finder study or as per the available information on the general toxicity of the test article.
The test item formulations are prepared in suitable vehicle and typically administered for period of at least 11 weeks before mating, during mating, and until necropsy. Cohabitation is done (ideally 1:1 ratio) with untreated female animals at least for a period of 14 days. The high dose is expected to produce evidence of toxicity whereas the mid and low doses are assigned to determine the dose response effects. Vaginal smears from females are made during the cohabitation for determining the stages of estrous and for the presence of sperm. After confirmation of positive mating, females are separated from the male, body weights recorded during gestation. On gestation day 13 to 15, females are euthanized, gross necropsy is conducted and the number of corpora lutea and the location and status of each implant site (live/dead embryo and early/late resorption) are recorded.
In males, after a period of one month of successful mating, necropsy is conducted, reproductive organs such as testis, epidydimides, seminal vesicles, and prostrate are collected and preserved for histopathology. Also, semen parameters such as sperm count, sperm motility and sperm viability are evaluated for test item related effects. Serum testosterone levels are also measured. Microscopic examination of testis and epidydimides is carried out for tissue level abnormalities.
Highly-skilled team of clinical pathologists
Highly customized study designs
Fast turnaround time
JUNE 28, 2022
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...Read More
JANUARY 04, 2021
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...Read More
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.